Yes, Dravet is their lead program; like us, ADOA is their second program.
Their Dravet program is a year or so ahead of PYC’s lead program in RP11. But PYC looks like its third program will enter the clinic ahead of Stoke.
What is of interest is that when Stoke announced Phase1/2a results in late March, it doubled the share price. It’s traced back a bit since. Market cap is now ~A$912m.
PYC Price at posting:
9.8¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)